ClinicalTrials.gg
RecruitingNCT05928767WoodstockUpdated Sep 28, 2026

Evaluation of the Clinical Frailty Scale (CFS) as a Risk Factor of Mortality in Adult Patients ≤65 Years of Age Admitted to Intensive Care for Septic Shock.

An observational study in Frailty and Septic Shock, sponsored by Centre Hospitalier de Lens. Recruiting at 5 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Centre Hospitalier de Lens · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Sep 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies in Frailty with a site in France — 23 open to participants now, 25 under way, none of them phase 3. Frailty · France.

Planned enrollment
16th of 32
200 · median 200
Started
2023
with 5 others
Observational
32 of 59
14 open now
Primary completion
2027-09
later than 12 of 24 live
Registered
36th of 59
by date

Among the 59 studies in Frailty with a site in France, this one is the 16th largest by planned enrollment of the 32 observational ones that give a count, is one of 6 that started in 2023, is one of 32 observational ones, reaches primary completion later than 12 of the 24 other live ones, and was the 36th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

23 of the 59 studies in Frailty with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Frailty with a site in France, or all of them as a file.
02

Study summary

The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.

In the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short/medium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.

The objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.

This analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.

Read the detailed description

Recent studies show the impact of frailty in a middle-aged or even young population of patients admitted to critical care in terms of mortality (13), and the persistent risk of impairment of physical and mental capacities after resuscitation (14). To date, few studies have looked at clinical frailty as a risk factor for mortality in a middle-aged or young population, more specifically those suffering from septic shock, which is already known to be a major factor in morbidity and mortality (15,16), with repercussions on long-term quality of life.

The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.

In the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short/medium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.

The objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.

This analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.

03

Conditions studied

  • Frailty
  • Septic Shock
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients admitted to intensive care will be studied for this study. Patients meeting the inclusion criteria and with no non-inclusion criteria will be included in the study after obtaining the patient's or relative's, if applicable, non-objection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥18 years and ≤ 65 years
  • Patient admitted to intensive care - resuscitation
  • Patient admitted for suspected or documented type 3 sepsis
  • Presence of vasopressor amines to maintain MAP > 65mmHg despite filling
  • Lactatemia ≥ 2 mmol/L on admission.

Exclusion criteria

Exclusion Criteria:

  • Patient moribund on admission
  • Patients with severe pre-existing dementia and/or cognitive decline, suffering from severe neurodegenerative diseases that prevent the patient from living independently at baseline, including mental illness requiring institutionalisation, including acquired or congenital mental retardation, etc.
  • Pregnant women or women in labour
  • Patients under guardianship or curatorship
  • Patients deprived of their liberty
  • Patient and/or family unable to speak or understand French.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. To show that the frailty score on admission is a risk factor for mortality at D28, independent of known risk factors, in young patients admitted to intensive care (ICU) for sepsis or septic shock.

    The odds ratio of frail patients to non-frail patients for the risk of all-cause death at D28

    Time frame: 28 days after inclusion

Secondary outcomes

  1. To study the association, independently of known risk factors, between the frailty score on admission and mortality at day 90.

    Time from admission to death or last news, censored at D90

    Time frame: 90 days after inclusion

  2. To study the association, independently of known risk factors, between the frailty score on admission and length of hospital stay

    The time between admission to IS and live discharge from hospital, death is considered a concurrent risk, the data are censored at 90 days

    Time frame: 90 days after inclusion

  3. To study the association, independently of known risk factors, between the frailty score on admission and the number of days with recourse to invasive therapies

    Number of days with mechanical ventilation, with amines, with recourse to extra-renal purification (EER) during the IS stay.

    Time frame: 90 days after inclusion

  4. To study the association, independently of known risk factors, between the frailty score on admission and readmission to critical care or hospitalisation before D90, among patients discharged alive from ICU before D90.

    Readmission to critical care or hospitalisation before D90, among patients discharged alive from ICU before D90.

    Time frame: 90 days after inclusion

  5. To study the association, independently of known risk factors, between the frailty score on admission and describe changes in frailty between ICU admission and D90 in patients alive at D90.

    Change in frailty score defined by the CFS (continuous) between admission and D90 (in hospital or at home).

    Time frame: 90 days after inclusion

  6. To study the association, independently of known risk factors, between the frailty score on admission and describe quality of life at D90 in patients alive at D90.

    Quality of life measured by the EQ5D score at D90 (in hospital or at home).

    Time frame: 90 days after inclusion

07

Study locations

5 of 5 sites recruiting
  • Ch Germon Et Gauthier
    Béthune, 62408, France
    Recruiting
    • Ghada SBOUI, Dr · Principal investigator
  • CH Boulogne sur Mer
    Boulogne-sur-Mer, 62321, France
    Recruiting
    • Charles DETOLLENAERE, Dr · Principal investigator
  • CHU de Dijon
    Dijon, 21079, France
    Recruiting
    • Jean-Pierre QUENOT, Pr · Principal investigator
  • CH de Lens
    Lens, France
    Recruiting
    • Guillaume DEGOUY, Doctor · Principal investigator
  • CHU Lille
    Lille, 59037, France
    Recruiting
    • Alexandre GAUDET, Dr · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 48 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2026 → Sep 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 3, 2023
StartActual
Aug 21, 2023
Primary completionEst.
Sep 18, 2027was Sep 2026
CompletionEst.
Nov 2027was Nov 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 29, 2026→Sep 18, 2027
Sep 28, 2026
Study completion
Nov 2026→Nov 2027
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion Sep 29, 2026→Sep 18, 2027
    Study completion Nov 2026→Nov 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05928767
Lead sponsor
Centre Hospitalier de Lens
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Aug 21, 2023
Primary completion
Sep 18, 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Guillaume DEGOUY, Dr
Contact
gdegouy@ch-lens.fr
03.21.69.12.34
MELANIE VERLAY
Contact
mverlay@ch-lens.fr
03.21.69.10.28

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion